Published in Cancer Weekly, August 25th, 2009
"Cancer research has long been a priority focus area at MedImmune and we are proud of the organization's hard work to achieve first-time-in-human-status for all three candidates," said Laurence Moore, M.D., Ph.D., vice president, clinical development, oncology. "We look forward to continuing to evaluate how managing the various biological targets inherent in these very different antibodies may potentially lead to better...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2009-08-25)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.